About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Mechanisms of Weight Loss With SGLT2 Inhibition

Mechanisms of Weight Loss With SGLT2 Inhibition

NCT02360774·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Beth Israel Deaconess Medical Center

With

Janssen Scientific Affairs, LLC

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Type 2 diabetes
2. BMI 25-45 kg/m2
3. Hemoglobin A1C \> 6.5% but \< 9%
4. Normal renal function (GFR \> 60)
5. Age 18-75

You may not be if

1. Type 1 diabetes
2. History of recurrent UTI or mycotic genital infections
3. Treatment with insulin or a GLP1 agent
4. Pregnant or breastfeeding

The record

StatusCompleted

PhasePhase 4

Taking part30

StartedFeb 2015

UpdatedAug 3, 2018

Conditions

Type 2 Diabetes Overweight Obesity

Where1

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States